Low molecular weight fucoidan LF2 improves the immunosuppressive tumor microenvironment and enhances the anti-pancreatic cancer activity of oxaliplatin
Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved..
Chemotherapy remains the cornerstone of pancreatic cancer treatment. However, the dense interstitial and immunosuppressive microenvironment frequently render the ineffective anti-tumor activity of chemotherapeutic agents. Macrophages play a key role in the tumor immunomodulation. In this study, we found that low molecular weight of fucoidan (LF2) directly regulated the differentiation of mononuclear macrophages into the CD86+ M1 phenotype. LF2 significantly upregulated the expressions of M1 macrophage-specific cytokines, including iNOS, IL-6, TNFα and IL-12. LF2 modulated macrophage phenotypic transformation through activation of TLR4-NFκB pathway. Furthermore, we observed that LF2 enhanced the pro-apoptotic activity of oxaliplatin (OXA) in vitro by converting macrophages to a tumoricidal M1 phenotype. Meanwhile, LF2 increased intratumoral M1 macrophage infiltration and ameliorated the immunosuppressed tumor microenvironment, which in turn enhanced the anti-pancreatic ductal adenocarcinoma (PDAC) activity of OXA in vivo. Taken together, our results suggested that LF2 could act as a TLR4 agonist targeting macrophages and has a synergistic effect against PDAC when combined with OXA.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:173 |
---|---|
Enthalten in: |
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 173(2024) vom: 29. März, Seite 116360 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Deng, Zhenzhen [VerfasserIn] |
---|
Links: |
---|
Themen: |
04ZR38536J |
---|
Anmerkungen: |
Date Completed 27.03.2024 Date Revised 27.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.biopha.2024.116360 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM369125517 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM369125517 | ||
003 | DE-627 | ||
005 | 20240327235950.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240301s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.biopha.2024.116360 |2 doi | |
028 | 5 | 2 | |a pubmed24n1351.xml |
035 | |a (DE-627)NLM369125517 | ||
035 | |a (NLM)38422657 | ||
035 | |a (PII)S0753-3322(24)00244-0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Deng, Zhenzhen |e verfasserin |4 aut | |
245 | 1 | 0 | |a Low molecular weight fucoidan LF2 improves the immunosuppressive tumor microenvironment and enhances the anti-pancreatic cancer activity of oxaliplatin |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 27.03.2024 | ||
500 | |a Date Revised 27.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved. | ||
520 | |a Chemotherapy remains the cornerstone of pancreatic cancer treatment. However, the dense interstitial and immunosuppressive microenvironment frequently render the ineffective anti-tumor activity of chemotherapeutic agents. Macrophages play a key role in the tumor immunomodulation. In this study, we found that low molecular weight of fucoidan (LF2) directly regulated the differentiation of mononuclear macrophages into the CD86+ M1 phenotype. LF2 significantly upregulated the expressions of M1 macrophage-specific cytokines, including iNOS, IL-6, TNFα and IL-12. LF2 modulated macrophage phenotypic transformation through activation of TLR4-NFκB pathway. Furthermore, we observed that LF2 enhanced the pro-apoptotic activity of oxaliplatin (OXA) in vitro by converting macrophages to a tumoricidal M1 phenotype. Meanwhile, LF2 increased intratumoral M1 macrophage infiltration and ameliorated the immunosuppressed tumor microenvironment, which in turn enhanced the anti-pancreatic ductal adenocarcinoma (PDAC) activity of OXA in vivo. Taken together, our results suggested that LF2 could act as a TLR4 agonist targeting macrophages and has a synergistic effect against PDAC when combined with OXA | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Fucoidan | |
650 | 4 | |a Macrophages | |
650 | 4 | |a Oxaliplatin | |
650 | 4 | |a Tumor microenvironment | |
650 | 7 | |a fucoidan |2 NLM | |
650 | 7 | |a 9072-19-9 |2 NLM | |
650 | 7 | |a Oxaliplatin |2 NLM | |
650 | 7 | |a 04ZR38536J |2 NLM | |
650 | 7 | |a Toll-Like Receptor 4 |2 NLM | |
650 | 7 | |a Antineoplastic Agents |2 NLM | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Polysaccharides |2 NLM | |
700 | 1 | |a Qishan, Suo |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Quanbin |e verfasserin |4 aut | |
700 | 1 | |a Wang, Jing |e verfasserin |4 aut | |
700 | 1 | |a Yue, Yang |e verfasserin |4 aut | |
700 | 1 | |a Geng, Lihua |e verfasserin |4 aut | |
700 | 1 | |a Wu, Ning |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie |d 1984 |g 173(2024) vom: 29. März, Seite 116360 |w (DE-627)NLM012645591 |x 1950-6007 |7 nnns |
773 | 1 | 8 | |g volume:173 |g year:2024 |g day:29 |g month:03 |g pages:116360 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.biopha.2024.116360 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 173 |j 2024 |b 29 |c 03 |h 116360 |